Nov. 15, 2011
/PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading
-based advanced in-vitro diagnostic ("IVD") company, today announced that it has made the payment for all outstanding principal and accrued interest with respect to its 3.5% Convertible Senior Subordinated Notes (the "2011 Notes") which matured on
November 15, 2011
. All of the outstanding 2011 Notes will be cancelled accordingly. None of the 2011 Notes were converted into shares of the Company.
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading
-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in
through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit
SOURCE China Medical Technologies, Inc.